{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigrt75jigwtlfbbdorei7huvc7bd4ops3ihgwp5medrc4mmnxjmsy",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mgnm7qni3tm2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidlnostgt5jbwwv6bhuj6adfbwdevct7dfdxiygrfgakvrzn6zvca"
    },
    "mimeType": "image/webp",
    "size": 76298
  },
  "path": "/releases/2026/03/260307213244.htm",
  "publishedAt": "2026-03-08T16:45:01.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "A massive UK study of more than 165,000 dementia patients has uncovered troubling new evidence about risperidone, a commonly used drug for severe agitation. Researchers found the antipsychotic increases stroke risk in dementia patients across the board—including those with no prior heart disease or stroke—challenging the long-held belief that some patients might be safer candidates than others. Because risperidone is the only drug of its type licensed for dementia, doctors often use it as a last resort when distressing symptoms become unmanageable.",
  "title": "165,000 dementia patients reveal hidden stroke risk from common drug"
}